Finasteride/tadalafil

{{Short description|Combination drug}}

{{Use American English|date=December 2021}}

{{Use dmy dates|date=December 2021}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| image2 =

| width2 =

| alt2 =

| caption =

| component1 = Finasteride

| class1 = 5α-reductase inhibitor

| component2 = Tadalafil

| class2 = Phosphodiesterase 5 (PDE5) inhibitor

| tradename = Entadfi

| Drugs.com = {{drugs.com|cons|finasteride-and-tadalafil}}

| MedlinePlus =

| DailyMedID = Finasteride and tadalafil

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = By mouth

| ATC_prefix = G04

| ATC_suffix = CB51

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Entadfi- finasteride and tadalafil capsule | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=112bf653-8322-4444-8d4d-03234b11c38c | access-date=24 December 2021}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D12486

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

}}

Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH).{{cite journal | vauthors = Elkelany OO, Owen RC, Kim ED | title = Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus | journal = Therapeutics and Clinical Risk Management | volume = 11 | issue = | pages = 507–13 | date = 2015 | pmid = 25848297 | pmc = 4386768 | doi = 10.2147/TCRM.S80353 | doi-access = free }}{{cite journal | vauthors = Olesovsky C, Kapoor A | title = Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia | journal = Therapeutic Advances in Urology | volume = 8 | issue = 4 | pages = 257–271 | date = August 2016 | pmid = 27928428 | pmc = 5131741 | doi = 10.1177/1756287216650132 }} It contains finasteride and tadalafil. It is taken by mouth.

It was approved for medical use in the United States in December 2021.{{cite press release | title=Veru Announces FDA Approval of Entadfi, a New Treatment for Benign Prostatic Hyperplasia | website=Veru | date=13 December 2021 | url=https://verupharma.gcs-web.com/news-releases/news-release-details/veru-announces-fda-approval-entadfi-new-treatment-benign | access-date=17 December 2021}}